Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moleculin Biotech CS (MBRX)

Moleculin Biotech CS (MBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,744
  • Shares Outstanding, K 2,036
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,760 K
  • EBIT $ -24 M
  • EBITDA $ -24 M
  • 60-Month Beta 1.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -4.38
  • Number of Estimates 2
  • High Estimate -3.25
  • Low Estimate -5.50
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.01 +20.63%
on 12/01/25
12.65 -42.70%
on 11/12/25
-4.97 (-40.70%)
since 11/07/25
3-Month
6.01 +20.63%
on 12/01/25
15.75 -53.97%
on 11/03/25
-2.48 (-25.45%)
since 09/08/25
52-Week
6.01 +20.63%
on 12/01/25
91.25 -92.05%
on 02/13/25
-58.50 (-88.97%)
since 12/06/24

Most Recent Stories

More News
Moleculin Announces New Annamycin Collaboration in Brain Tumors

Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multiforme  Research will evaluate effects of intra-arterial delivery of Annamycin HOUSTON, Dec....

MBRX : 7.25 (+0.14%)
Moleculin to Participate in the Virtual Investor Closing Bell Series

Live video webcast with Walter Klemp, Chairman and Chief Executive Officer, on Tuesday, December 2 nd at 4:00 PM ET HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq:...

MBRX : 7.25 (+0.14%)
Moleculin Announces Reverse Stock Split

HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate...

MBRX : 7.25 (+0.14%)
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Completion of treatment for the first 45 patients on pace for Q1 2026 with initial unblinded data thereafter; blinded response activity tracking within expected range HOUSTON, Nov. 13, 2025 (GLOBE...

MBRX : 7.25 (+0.14%)
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Preclinical research to be conducted at the University of North Carolina at Chapel Hill (UNC)  Annamycin will be used in conjunction with novel agents and modalities Preclinical studies indicate...

MBRX : 7.25 (+0.14%)
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates...

MBRX : 7.25 (+0.14%)
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates...

MBRX : 7.25 (+0.14%)
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 study Preclinical studies indicate Annamycin targets key factors in pancreatic...

MBRX : 7.25 (+0.14%)
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates...

MBRX : 7.25 (+0.14%)
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

European expansion in September across Georgia, Italy, Lithuania, Poland, Romania, Spain, and US 13 subjects recruited (treated, enrolled, or screened) Forecasts total recruitment of 20 or more...

MBRX : 7.25 (+0.14%)

Business Summary

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia....

See More

Key Turning Points

3rd Resistance Point 8.79
2nd Resistance Point 8.38
1st Resistance Point 7.82
Last Price 7.25
1st Support Level 6.85
2nd Support Level 6.44
3rd Support Level 5.88

See More

52-Week High 91.25
Fibonacci 61.8% 58.69
Fibonacci 50% 48.63
Fibonacci 38.2% 38.57
Last Price 7.25
52-Week Low 6.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar